Meiji Seika and Eisai Enter into a Collaboration for the Development and Commercialization of Safinamide in Parkinson’s Disease for Japan and Asia
- October 24, 2018
- Posted By : admin
- 0 Comment
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; CEO: Daikichiro Kobayashi, “Meiji”) announced today that they have
error: Content is protected !!